Dual conjugation process for preparing antibody-drug conjugates
The present invention relates to a process for preparing antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.
1. A process for preparing an antibody-drug conjugate, which comprises an antibody and therapeutic moieties conjugated to the antibody, the process comprising the steps of:
(a) selectively reducing a cysteine-engineered antibody comprising reacting an antibody comprising one or more engineered cysteines at positions selected from heavy chain 40, 41, and 89 according to the Kabat numbering system, heavy chain 152, 153, 155, and 171 according to the Eu numbering system, light chain 40 and 41 according to the Kabat numbering system, and light chain 165 and 168 according to the Eu numbering system, with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII)
or a salt thereof;
(b) further reducing the selectively reduced antibody of step (a) with an interchain disulfide bond reducing agent to form one or more reduced interchain cysteines; and
(c) conjugating therapeutic moieties via cleavable or non-cleavable linkers to the one or more engineered cysteines and to at least one reduced interchain cysteine of the further reduced antibody of step (b).
2. The process according to claim 1 , wherein the compound according to formula (I), (II), (III), (IV), (V), (VI), (VII), or a salt thereof is present in an amount of at least one molar equivalent per molar amount of engineered cysteine.
3. The process according to claim 2 , wherein the compound according to formula (I), (II), (III), (IV), (V), (VI), (VII), or a salt thereof is present in an amount of from 2 to 16 molar equivalents per molar amount of engineered cysteine.
4. The process according to claim 3 , wherein the cysteine-engineered antibody is reacted with a compound of formula (I) or (II), or a salt thereof.
5. The process according to claim 4 , wherein the antibody comprises one or more engineered cysteines at positions selected from heavy chain 41 and light chain 40 and 41.
6. The process according to claim 3 , wherein the antibody comprises one or more engineered cysteines at positions selected from heavy chain 41 and light chain 40 and 41.
7. The process according to claim 2 , wherein the cysteine-engineered antibody is reacted with a compound according to formula (I), (II), (III), or a salt thereof.
8. The process according to claim 1 , wherein the interchain disulfide bond reducing agent is tris(3-sulfophenyl)phosphine, tris(2-carboxyethyl)phosphine or dithiothreitol.
9. The process according to claim 1 , wherein the interchain disulfide bond reducing agent is present in an amount of more than 0.1 molar equivalents per molar of antibody.
10. The process according to claim 9 , wherein the interchain disulfide bond reducing agent is present in an amount of from 0.25 to 3 molar equivalents per molar of antibody.
11. The process according to claim 10 , wherein the interchain disulfide bond reducing agent is tris(3-sulfophenyl)phosphine, tris(2-carboxyethyl)phosphine or dithiothreitol.
12. The process according to claim 10 , wherein the antibody-drug conjugate has an average DAR of from 2.0 to 6.0.
13. The process according to claim 11 , wherein the antibody-drug conjugate has an average DAR of from 2.0 to 6.0.
14. The process according to claim 1 , wherein the antibody comprises one or more engineered cysteines at positions selected from heavy chain 40, 41, 152, and 153 and light chain 40, 41, and 165.
15. The process according to claim 14 , wherein the antibody comprises a single engineered cysteine at a position selected from heavy chain 41 and light chain 40 and 41.
16. The process according to claim 15 , wherein the antibody-drug conjugate has an average DAR of at least 2.2.
17. The process according to claim 15 , wherein the antibody-drug conjugate has an average DAR of from 2.0 to 6.0.
18. The process according to claim 1 , wherein the antibody-drug conjugate has an average DAR of at least 2.2.
19. The process according to claim 1 , wherein the antibody-drug conjugate has an average DAR of from 2.0 to 6.0.
20. The process according to claim 1 , wherein the antibody is a monospecific or bispecific antibody or antibody fragment comprising at least one heavy chain and light chain variable region binding to a target selected from the group consisting of annexin A1, B7H4, CA6, CA9, CA15-3, CA19-9, CA27-29, CA125, CA242, CCR2, CCR5, CD2, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD47, CD56, CD70, CD74, CD79, CD115, CD123, CD138, CD203c, CD303, CD333, CEA, CEACAM, CLCA-1, CLL-1, c-MET, Cripto, DLL3, EGFL, EGFR, EPCAM, EPh, endothelin B receptor (ETBR), FAP, FcRL5 (CD307), FGFR, FOLR1, GCC, GPNMB, HER2, HMW-MAA, integrin α, IGF1R, TM4SF1, Lewis A like carbohydrate, Lewis X, Lewis Y, LIV1, mesothelin, MUC1, MUC16, NaPi2b, Nectin-4, PD-1, PD-L1, PSMA, PTK7, SLC44A4, STEAP-1, 5T4 antigen, TF (tissue factor), TF-Ag, Tag72, TNFR, TROP2, VEGFR and VLA.
21. The process according to claim 1 , wherein said therapeutic moiety is selected from the group consisting of a duocarmycin, a CBI dimer, a calicheamicin, a PBD, a PBD dimer, a maytansinoid, a tubulysin, a camptothecin, an amanitin, and an auristatin derivative.